Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

John Carroll FierceBiotech News

Are specialty pharma CEOs worth their salt?

Carly Helfand Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs? FiercePharma ...

Report: In a big split, Baxter looks to relocate biopharma to Boston

John Carroll For months now rumors of a big prospective biotech relocation have been circulating in the hot Boston hub. And now the Boston Business Journal, a weekly with its ear to ...

FDA clears Glaxo Ebola vaccine for speedy human trials

Carly Helfand GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials. FiercePharma News

PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Tracy Staton Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases ...

What’s the #1 biotech hub for VCs? (It’s still not Boston)

John Carroll Biotech investing is sizzling right now, and despite all the attention that the Boston hub gets, the Bay Area is still number one. FierceBiotech News

Back on the ‘hot’ list, Achillion shares spike (yet again) on takeover talk

John Carroll Ted Tenthoff, an analyst for Piper Jaffray, was clearly pumped about the prospects of an Achillion buyout when a reporter from Bloomberg reached him. FierceBiotech News

Study sounds alarm on sleep-aid ingredient zolpidem

Carly Helfand Sleep aids have landed in the safety spotlight recently, with regulatory agencies lowering dosages on some meds to ease side effect worries. But overmedication has its ...

Celebrity pitch-folks may not be worth the money, study finds

Tracy Staton Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods? FiercePharma ...

UPDATED: Kite Pharma soars on added evidence that CAR-T treatment quells cancer

John Carroll Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in ...

Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Damian Garde Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market ...

Don’t worry about a hep C pricing war, analysts tell Gilead-watchers

Tracy Staton No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS